Release Details

Paris, 1st September 2015 – ABIVAX (Euronext Paris: ABVX), a Paris-based leading clinical stage biotech company developing and commercializing anti-viral compounds and human vaccines, today announced that it will publish its financial results for the first half of 2015 on September 29, 2015, post-market.  The results will also be made available on the company’s website, www.abivax.com.